Enhanced analgesic activity of D-Ala2 enkephalinamides following D-isomer substitutions at position five
References (15)
- et al.
Life Sci.
(1977) - et al.
Brain Res. Bull.
(1977) - et al.
Biochem. Biophys. Res. Commun.
(1976) - et al.
Pharmacol. Biochem. Behav.
(1976) - et al.
Brain Res. Bull.
(1976) - et al.
Nature
(1976) - et al.
Nature
(1975)
There are more references available in the full text version of this article.
Cited by (14)
Factors that restrict the cell permeation of cyclic prodrugs of an opioid peptide, part 3: Synthesis of analogs designed to have improved stability to oxidative metabolism
2012, Journal of Pharmaceutical SciencesCitation Excerpt :A major challenge in making these chemotypes orally bioavailable lies in improving the biopharmaceutical properties of the peptides and peptidomimetics while maintaining their high affinity for their pharmacological receptors. For example, H-Tyr–d-Ala–Gly–Phe–d-Leu—OH (DADLE) was developed as a biologically active opioid peptide that is resistant to peptidase.10,11 However, this opioid peptide exhibits poor permeation across biological barriers such as the blood–brain barrier and intestinal mucosa.9,12–16
Delta opioid receptor radioligands
1992, Biochemical PharmacologyEnkephalin-like character and analgesia
1981, European Journal of PharmacologyStructure-activity relationships of enkephalin analogs at opiate and enkephalin receptors: Correlation with analgesia
1980, European Journal of Pharmacology1 Endogenous Opioid Peptides - The Enkephalins and Endorphins
1980, Progress in Medicinal Chemistry
Copyright © 1978 Published by Elsevier Inc.